Abstract 26: The Corrie Myocardial infarction, COmbined-device, Recovery Enhancement (MiCORE) Study: 30-Day Readmission Rates and Cost-Effectiveness of a Novel Digital Health Intervention for Acute Myocardial Infarction Patients

Abstract

Purpose: Determine if acute myocardial infarction (AMI) patients using a novel digital health intervention, the Corrie Health Digital Platform (Corrie), have reduced 30-day hospital readmissions and related healthcare costs compared to a historical comparison group. Methods: Corrie is deployed to patients admitted to Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center, Massachusetts General Hospital, and Reading Hospital for an AMI (STEMI or type 1 NSTEMI), as early as possible during their hospitalization in the inpatient cardiac units. AMI patients are enrolled if they are: over 18 years old; English-speaking; without auditory, visual, cognitive, or physical impairment; and own a smartphone. Corrie is deployed to patients using a standard operating procedure and consists of the following: (1) a smartphone medication, education, vitals, and follow-up appointments self-management app, (2) smartwatch for reminders and heart rate and physical activity tracking, and (3) a Bluetooth-enabled blood pressure cuff. Patients are either enrolled with their personal iPhone or a loaner iPhone, if they own any other type of smartphone, and a loaner smartwatch for usage during the 30 day study period. The historical comparison group consists of AMI patients, admitted at the same hospitals from October 1 st 2015-2016, who did not receive Corrie. All-cause readmission rates will be evaluated at 30 days after discharge in both groups and Cox proportional hazard models will be used to test differences in time to all-cause first readmission within 30 days between groups, controlling for covariates. To assess cost-effectiveness of Corrie, a Markov Model of cost-effectiveness will be built, based on 30-day readmission rates, to assess the Incremental Cost-Effectiveness Ratio of adopting Corrie. Results/Conclusions: The MiCORE study is being completed and results will be available for AHA QCOR by April 2019.